Author + information
- Received December 8, 2009
- Revision received February 26, 2010
- Accepted March 18, 2010
- Published online September 21, 2010.
- Pradeep Gujja, MD⁎,⁎ (, )
- Douglas R. Rosing, MD†,
- Dorothy J. Tripodi, RN† and
- Yukitaka Shizukuda, MD, PhD⁎,†
- ↵⁎Reprint requests and correspondence:
Dr. Pradeep Gujja, Division of Cardiovascular Disease, Department of Internal Medicine, University of Cincinnati, 231 Albert Sabin Way, ML 0542, Cincinnati, Ohio 45267-0542
The prevalence of iron overload cardiomyopathy (IOC) is increasing. The spectrum of symptoms of IOC is varied. Early in the disease process, patients may be asymptomatic, whereas severely overloaded patients can have terminal heart failure complaints that are refractory to treatment. It has been shown that early recognition and intervention may alter outcomes. Biochemical markers and tissue biopsy, which have traditionally been used to diagnose and guide therapy, are not sensitive enough to detect early cardiac iron deposition. Newer diagnostic modalities such as magnetic resonance imaging are noninvasive and can assess quantitative cardiac iron load. Phlebotomy and chelating drugs are suboptimal means of treating IOC; hence, the roles of gene therapy, hepcidin, and calcium channel blockers are being actively investigated. There is a need for the development of clinical guidelines in order to improve the management of this emerging complex disease.
Dr. Gujja reports that he has no relationships to disclose. Research work of Dr. Rosing and Ms. Tripodi is supported by a fund from the intramural research programs of the NHLBI/NIH. Dr. Shizukuda is a special volunteer investigator of the National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI/NIH), and his research is in part supported by a fund from the intramural research programs of the NHLBI/NIH.
- Received December 8, 2009.
- Revision received February 26, 2010.
- Accepted March 18, 2010.
- American College of Cardiology Foundation